The Immunological Monitoring Core provides immunologic and biological assay support for ongoing research projects and clinical trials at the Cancer Center and the biomedical community at the University of Michigan. Services are provided in three different areas. First, simultaneous detection of numerous cytokines, chemokines, hormones and other released proteins and the related technical support are provided on a continued basis for investigators. These assays are performed with the Luminex System, and via ELISA using a robotics pipetting station. Second, TAA-specific T cell response assays will be provided to investigators. These assays Include TAA-specific cytokine ELISA spot by using the AID ELISPOT Plate Reader, and TAA-specific T cell proliferation and CTL activities. Third, the Core provides time standard technical services to support clinical research protocols in the immunobiology area for Investigators who do not have standard wet laboratory space. This facility will provide the opportunity to have tissues processed and analyzed for general immune parameters, standard lymphocyte and tumor proliferation assays, as well as quantification of cytokines. These Immune assays may not nomially be available In the non-immunology laboratory, The Core also provides expert advice that helps investigators select appropriate immune assays using appropriate reagents and apply them to best advantage.
The services provided by the immune Monitoring Core support research by investigators involved in immunological approaches to the treatment of cancer. The overall goal of this core is to extend or improve the quality of life of cancer patients through immune mechanisms.
|Verhaegen, Monique E; Mangelberger, Doris; Harms, Paul W et al. (2015) Merkel cell polyomavirus small T antigen is oncogenic in transgenic mice. J Invest Dermatol 135:1415-24|
|Chinn, Steven B; Darr, Owen A; Owen, John H et al. (2015) Cancer stem cells: mediators of tumorigenesis and metastasis in head and neck squamous cell carcinoma. Head Neck 37:317-26|
|Vainshtein, Jeffrey M; Spector, Matthew E; Stenmark, Matthew H et al. (2014) Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer. Oral Oncol 50:234-9|
|Castro, Maria G; Candolfi, Marianela; Wilson, Thomas J et al. (2014) Adenoviral vector-mediated gene therapy for gliomas: coming of age. Expert Opin Biol Ther 14:1241-57|
|Vainshtein, Jeffrey M; Spector, Matthew E; McHugh, Jonathan B et al. (2014) Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. Oral Oncol 50:513-9|
|Grogan, Patrick T; Sarkaria, Jann N; Timmermann, Barbara N et al. (2014) Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. Invest New Drugs 32:604-17|
|VanderVeen, Nathan; Paran, Christopher; Appelhans, Ashley et al. (2014) Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors. Mol Ther Methods Clin Dev 1:|
|Krook, Melanie A; Nicholls, Lauren A; Scannell, Christopher A et al. (2014) Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma. Mol Cancer Res 12:953-64|
|Ro, Seung-Hyun; Semple, Ian A; Park, Haewon et al. (2014) Sestrin2 promotes Unc-51-like kinase 1 mediated phosphorylation of p62/sequestosome-1. FEBS J 281:3816-27|
|Stenmark, Matthew H; McHugh, Jonathan B; Schipper, Matthew et al. (2014) Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int J Radiat Oncol Biol Phys 88:580-8|
Showing the most recent 10 out of 862 publications